Chronic myeloid leukemia (CML) care teams are challenged to stay on top of the latest advances and best practices for tyrosine kinase inhibitor (TKI) therapies. Is your team up to date with the most recent guideline recommendations, clinical evidence and drug optimization strategies across generations of TKIs? Tune in to this recording of a live webinar where leading CML experts discuss: The latest efficacy and safety clinical trial data and real-world evidence for TKIs in CML management Guideline recommendations for selection and sequencing of TKIs across lines of therapy Best practices for incorporating clinical evidence, disease characteristics, and patients’ preferences and goals into personalized treatment decision-making Strategies for dose-optimization and adverse event management Audience questions during our Ask the Expert Q&A.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/changing-inertia-equipping-community-oncology-providers-leading-strategies
- Start Date: 2024-12-05 06:00:00
- End Date: 2024-12-05 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 74750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology